Pricing for new drugs lacks transparency
The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers. Writing in the Journal of the Royal Society of Medicine, the authors of an essay on market-access agreements for anti-cancer drugs, say that while the underlying strategy is to help reduce the likelihood of health systems paying for treatments that turn out not to be cost-effective, the agreements can also be seen as an opportunistic way for pharmaceutical manufacturers to keep official prices high.
The authors of the essay, from University College London and the Mario Negri Institute for Pharmacological Research in Milan, conducted a comparative analysis of market-access agreements in oncology in the English and Italian health systems. Dr Livio Garattini, of the Mario Negri Institute, said: “England and Italy were the first countries to introduce market-access agreements on specific drugs almost a decade ago and our aim was to assess the experiences of both countries.”
There are two types of market-access agreements. Financial-based schemes, favoured by the English NHS, focus on the budget impact of a new drug and consist of price/dose discounts. Performance-based schemes, predominant in the Italian health system, involve collecting clinical evidence and lead to payment only for patients responding to the new therapy.
“The emotive nature of cancer makes it difficult for health agencies to resist calls for reimbursement of even extremely expensive drugs with marginal efficacy,” said Dr Garattini. “While performance-based schemes are not without political appeal, they contribute little to robust clinical assessment in practice. Simple financial-based contracts seem more efficient as a means for health services to reduce outlay on costly anti-cancer drugs and achieve access for patients.”
However, the financial arrangements between pharmaceutical manufacturers and the health systems paying for the new drugs are kept commercial-in-confidence, leading the authors to conclude that when market-access agreements lead to prices which are not transparent, the schemes simply penalise those countries which rely on external reference pricing. “This lack of transparency raises an issue of public interest on the international level,” said Dr Garattini.
Notes to editors
Market-access agreements for anti-cancer drugs (DOI: 10.1177/0141076814559626:) by Katelijne van de Vooren, Alessandro Curto, Nick Freemantle and Livio Garattini will be published by the Journal of the Royal Society of Medicine at 00:05hrs (UK) time Tuesday 9 December 2014.
For further information or a copy of the paper please contact:
Media Office, Royal Society of Medicine
DL +44 (0) 1580 764713
M +44 (0) 7785 182732
The JRSM is the flagship journal of the Royal Society of Medicine and is published by SAGE. It has full editorial independence from the RSM. It has been published continuously since 1809. Its Editor is Dr Kamran Abbasi.
SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology, and medicine. An independent company, SAGE has principal offices in Los Angeles, London, New Delhi, Singapore and Washington DC. www.sagepublications.com
Contact (media inquiries only)
- Louise Coady, Head of Corporate Communications and Public Affairs: firstname.lastname@example.org / Tel: (+44) (0)7810 807291